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Abstract
Background: Clonal competition in cancer describes the process in which the progeny of a cell clone supersedes
or succumbs to other competing clones due to differences in their functional characteristics, mostly based on
subsequently acquired mutations. Even though the patterns of those mutations are well explored in many tumors,
the dynamical process of clonal selection is underexposed.
Methods: We studied the dynamics of clonal competition in a BcrAbl-induced leukemia using a γ-retroviral vector
library encoding the oncogene in conjunction with genetic barcodes. To this end, we studied the growth dynamics
of transduced cells on the clonal level both in vitro and in vivo in transplanted mice.
Results: While we detected moderate changes in clonal abundancies in vitro, we observed monoclonal leukemias
in 6/30 mice after transplantation, which intriguingly were caused by only two different BcrAbl clones. To analyze
the success of these clones, we applied a mathematical model of hematopoietic tissue maintenance, which indicated
that a differential engraftment capacity of these two dominant clones provides a possible explanation of our
observations. These findings were further supported by additional transplantation experiments and increased BcrAbl
transcript levels in both clones.
Conclusion: Our findings show that clonal competition is not an absolute process based on mutations, but highly
dependent on selection mechanisms in a given environmental context.
Keywords: BcrAbl, Genetic barcodes, Leukemia, Heterogeneity, Clonal dynamics, Mathematical modelling, Clonal
competition
Background
Genome instability resulting in increasing intratumoral
heterogeneity is one of the enabling characteristics of
cancer [1]. In consequence, acquired intrinsic selective
advantages may result in the dominance of the most
competitive malignant clones under the given condi-
tions. Furthermore, both intracellular and extracellular
factors influence tumor growth and intratumoral clonal
competition, including the (dysregulated) epigenome
and the local microenvironment [2–4]. Occurrence of
resistances is a typical example of such setting, in which
an initially small, but preexisting and therapy-resistant
tumor clone might only outgrow under a therapy that
targets the non-resistant part of the tumor [5, 6].
Deep sequencing of individual cells from tumor sam-
ples to decipher their mutational load has fostered the
understanding of clonal evolution during cancer pro-
gression. It allows to retrospectively identify the most
competitive cell clones and to estimate the order of gen-
omic alterations. Despite these successes, the precise
timing of mutation occurrence is hardly reconstructable.
Moreover, an accurate, retrospective estimation of the
clonal dynamics of newly evolving, but successively out-
competed cell clones is difficult to obtain. However,
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analysis of inferior clones is necessary to understand
tumor progression as a temporally extended, dynamic
competition process of diverging cell clones.
Alternative approaches for studying clonal dynamics
aim at prospectively marking individual cell clones (e.g.,
by using integrating viral vectors) and studying temporal
development by tracking the viral integration sites (IS)
or genetic barcodes delivered by the viral vector (see e.g.
[7–12]). Such marking strategies are not able to recon-
struct the emergence of newly mutated cell clones, be-
cause the marking event occurs before the novel
mutation. However, they qualify to mark an already het-
erogeneous population, to investigate the temporal de-
velopment of distinct clones, e.g. under different culture
conditions, and thereby to study the inter-clonal compe-
tition process [13]. To investigate the clonal interplay
during leukemic development, we and others explored
the option to combine genetic barcodes with a
leukemia-driving oncogene [14, 15].
Chronic myeloid leukemia (CML) is a hematologic dis-
order, characterized by increased myeloid cell counts in
peripheral blood. CML is one of the few cancer entities, in
which the driving mutation is clearly defined by a genomic
translocation of chromosome 9 and 22, in which the 5′-
end of Bcr is fused to the 3′-end of the proto-oncogene
Abl1. The resulting fusion protein BcrAbl is a constitu-
tively active protein tyrosine kinase, which leads to unim-
peded cell proliferation [16]. The BcrAbl oncogene is the
sole driving force to initially transform affected cells both
in vitro and in vivo [17–19].
We made use of this oncogenic potential of BcrAbl to
study clonal developments of leukemia in vitro and in
vivo. In particular, we applied γ-retroviral vectors to
both, deliver the BcrAbl oncogene and to unambigu-
ously mark modified cells with a genetic barcode. We
transduced IL-3-dependend Ba/F3 cells, which can be
maintained in vitro but also transplanted into mouse re-
cipients. We thus investigated whether the initially poly-
clonal composition of differently marked, BcrAbl-
expressing cell clones was retained in vitro and during
development of a murine CML-like disease in vivo. Fi-
nally, we molecularly characterized dominant clones
from diseased mice.
Our study provides insights in the clonal dynamics
resulting from intratumoral heterogeneity beyond muta-
tional differences and into the different behaviors of
leukemic cells both in vitro and in vivo.
Methods
Cloning of the BcrAbl barcode vector library and
production of viral particles
The p210 BcrAbl wildtype construct [20] was cloned
into the γ-retroviral vector MP91-IRES-eGFP [21, 22]
together with the eGFP marker. The BC32-construct as
described in Thielecke et al. [23] was introduced into
the viral backbone by Gibson assembly [24]. The plas-
mid library was used for production of eco-pseudotyped
retroviral particles as described [25].
In vitro testing of vector construct
BcrAbl-BC vectors were used for transduction of Ba/F3
cells, which are strongly IL-3 dependent murine
hematopoietic cells and initially described as B-cell pre-
cursors [26] to induce factor independence [27]. Ana-
lyses were performed in triplicates. Three days after
transduction, samples were analyzed for eGFP expres-
sion and split, one half was still kept in IL-3-containing
medium, the other was washed and seeded in medium
without IL-3. Cells were passaged every 2 to 3 days,
eGFP expression was measured via flow cytometry (FC)
(LSR Fortessa, BD Bioscience, San Diego, CA, USA).
Cell samples of every passage were taken for DNA ex-
traction over a period of 45 days (including one freeze-
thawing process). On day 25 and on day 45, a portion of
the mixed population was sorted into eGFP-positive and
eGFP-negative cells (Aria IIIu, BD Bioscience) (Fig. 1).
In vivo experiments
On day 29, 1000 or 10,000 cells from the eGFP-positive
culture were transplanted into immune-competent, non-
conditioned Balb/C mice (n = 15 each). Blood samples
were taken on day 11 after transplantation. On days 21–
23, when some mice showed symptoms of leukemia, all
mice were sacrificed and hematopoietic organs [periph-
eral blood (PB), bone marrow (BM) and spleen (Spl)]
were isolated. After erylysis, cells were used for FC ana-
lysis and DNA extraction.
Another transplantation experiment was performed
with cells cultivated in vitro for 49 days after transduc-
tion. Fourteen recipient mice were transplanted with
10,000 eGFP-positive cells each. On day 15, all mice
showed signs of leukemia and were sacrificed for ana-
lysis as described before. Additionally, cells from spleens
were used for expansion in vitro.
Next-generation sequencing and bioinformatical analyses
1010 plasmids of the plasmid library or 200ng of gen-
omic DNA (representing approx. 30,000 genomic equiv-
alents) were subjected to PCR. Shortly, barcodes were
amplified and Illumina-TruSeq Adaptor sequences were
directly added (including Illumina based sample tags) in
a single PCR step (Multiplex Plus Kit, Qiagen,
Germany). Pooled libraries were quality-checked by
capillar electrophoresis (Fragment Analyzer, Advanced
Analytical, Ankeny, IA, USA) and sequenced with 83bp
single reads on a Miseq (Illumina, San Diego, CA, USA).
NGS-derived FASTQ-files were quality-filtered accord-
ing to the associated Phred-score (accepted Phred-
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score>30). Barcode sequences were subsequently ex-
tracted and processed applying a newly developed error-
correction method [23].
Integration site analysis
Ligation-mediated (LM)-PCR was performed as de-
scribed earlier [28]. Obtained sequences were analyzed
using the MAVRIC online Tool [29].
Transcript levels and RNA sequencing
In vitro cultured spleen cells from leukemic mice and as
controls, sorted BcrAbl-transduced Ba/F3-bulk cells and
untransduced Ba/F3 cells were subjected to RNA extrac-
tion (RNA Mini Kit, Qiagen) and subsequent cDNA syn-
thesis (First strand cDNA Synthesis Kit, Thermo Fisher
Scientific, Waltham, MA, USA). To determine transcript
levels of BcrAbl in the respective clones, TaqMan-based
real-time duplex PCR was performed with Gapdh as
reference gene (Additional file 1: Table S3). For quantifi-
cation, 101–106 copies of a clinically approved plasmid
standard for BcrAbl [30] were measured in relation to a
Gapdh plasmid standard (102–108 copies, Dharmacon
Inc., Lafayette, CO, USA).
RNA samples were subjected to the standard workflow
for strand-specific RNA-Seq library preparation (Ultra
Directional RNA Library Prep, NEB) and were se-
quenced on an Illumina HiSeq 2500. Basic quality con-
trol of the reads was performed using FastQC (http://
www.bioinformatics.babraham.ac.uk/). In addition, li-
brary diversity was assessed by redundancy investigation.
Alignment of the reads to the mouse reference (mm10)
was done with GSNAP (v2014–12-17) [31]. Ensembl
gene annotation version 75 was used to detect splice
sites. Uniquely aligned reads were counted with feature-
Counts (v1.4.6) [32] and the same Ensembl annotation.
Normalization of the raw read-counts based on the
a
b
Fig. 1 Vector construction and experimental set-up. a Wildtype BcrAbl (p210) in conjunction with eGFP was cloned into the γ-retroviral vector MP91
[21, 22]. The viral backbone was additionally equipped with a truncated sequence of Illumina Adaptors and our BC32 construct [23]. 1010 plasmids of
the obtained plasmid library were used for next-generation sequencing via Miseq (Illumina) and >80,000 different plasmids were obtained. b BcrAbl-
barcode containing viral particles were used to transduce the IL-3-dependent murine hematopoietic cell line Ba/F3. After IL-3 withdrawal, the cells
were kept in culture and every 2–4 days an aliquot of cells was analysed by FC and used for DNA extraction. Cells were sorted for eGFP on day 24 (i)
and on day 45 (ii) (after thawing). eGFP-positive cells were taken and transplanted into non-conditioned female Balb/C mice on day 29 (i) (1000 or
10,000 cells per mouse) and on day 49 (ii) (10,000 cells per mouse)
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library size and testing for differential expression be-
tween the three conditions (A, B and BcrAbl_bulk) was
performed with the DESeq2 R-package (v 1.8.1) [33]. Genes
with an adjusted p-value of less than 0.1 were considered
as differentially expressed. KEGG gene set enrichment ana-
lysis was done with the clusterProfiler R-package [34].
Simulations
We utilized an established single-cell based model frame-
work for murine and human hematopoiesis [35–39]. For
cells of all relevant clones (A, B, BcrAbl_bulk) we assumed
a distribution of their engraftment capability (encoded by
their initial attachment affinity), reflecting the fact that
clone A and B have an increased probability for engraft-
ment. From these distributions we sampled the corre-
sponding number of cells that were observed in the
analysis of the sequenced graft and used those to initialize
the single-cell based model. In contrast to the host cells
(which were initialized with the standard parameter set
[38]), transplanted leukemic cells had an overall competi-
tive advantage (i.e. increased proliferation rate encoded by
altered transition functions, Additional file 1: Table S2).
Every in silico transplantation was carried out mimicking
an unconditioned host. Engraftment response was calcu-
lated as average over 250 transplantations. The second set
of transplantations followed the same procedure only with
adjusted cell numbers for the leukemic clones.
Results
BcrAbl-barcode vector transformed Ba/F3 cells to IL-3 in-
dependency in vitro
We generated a γ-retroviral plasmid vector library with
BcrAbl and eGFP in conjunction with our BC32 barcode
[23] that contained >80,000 different barcodes (Fig. 1a).
Transduction of 100,000 Ba/F3 cells with viral particles de-
rived from this library resulted in 2.5% eGFP-positive cells
with a high probability for unique integrations. This initial
transduction level declined slightly over time in the pres-
ence of IL-3, whereas cytokine deprivation led to a rapid
increase to 60% eGFP-positive cells, followed by a slow de-
crease to 50% after 45 days (Additional file 1: Figure S1A).
Prior to transplantation, we sorted the eGFP-positive cells
from the BcrAbl_bulk culture on day 25 and on day 45.
Clonal marking reveals polyclonal dynamics in vitro
NGS of freshly transduced Ba/F3 cells revealed 158 dif-
ferent barcodes, of which 148 barcodes (93.7%) were
previously detected within the >80,000 barcodes from
the plasmid library (Additional file 1: Figure S2). The
initial number declined to 114 barcodes during in vitro
culture (Additional file 1: Figure S1B). We also observed
variability in clone sizes between consecutive time
points. As the overall change in clonal abundances ap-
peared modest, we suspect that various measurement
errors further affected quantification. Fluctuations may
have resulted from sampling effects during cell culture
as well. We observed more pronounced changes in the
clonal dynamics after sorting eGFP-positive cells. In fact,
we detected a drop in the overall number of clones
(probably due to the loss of eGFP-negative, but vector-
positive clones), and an increase in the relative contribu-
tion of single clones (Additional file 1: Figure S3).
In vivo tumorigenicity drives monoclonality in developing
leukemias
We transplanted either 1000 (n = 15 each) or 10,000
eGFP-positive cells (n = 15 each) to address a potential
impact of cell numbers. When six mice from the second
group showed signs of leukemia (on days 21–23 after
transplantation), all mice were sacrificed in accordance
with the experimental setup. Diseased mice had enlarged
spleens (Additional file 1: Table S1 and Figure S4), and
eGFP-positive cells were detected in PB, BM and spleen
(Fig. 2a). In all other mice, no signs of leukemia were ob-
served, and no eGFP-positive cells were detected. We
isolated DNA from PB, BM and spleen of leukemic mice
for barcode amplification and NGS (Fig. 2b). We identi-
fied only one dominant clone per animal responsible for
the leukemic outgrowth and surprisingly, only two dif-
ferent clones in total. Leukemia in two mice resulted
from one clone (termed “A”, marked in green); the other
four mice were dominated by a second clone (“B”,
marked in blue). In the original graft (day 29), these two
clones were minor, only 0.47% of all reads contained bar-
code of clone A, whereas 0.65% contained barcode of
clone B.
To investigate, whether these two clones were only suc-
cessful by chance, we performed a second series of trans-
plantations: 14 mice received 10,000 eGFP-positive cells
from a second sort at day 49 of in vitro culture (compare
Fig. 1). After 15 days, all mice showed signs of leukemia
and were sacrificed. They all had enlarged spleens and
eGFP-positive cells in all analyzed hematopoietic organs
(PB, BM, spleen) (Additional file 1: Table S1 and Figure S4).
Sequence analysis revealed that the majority of read counts
in each mouse again represented the same two clones A
and B, which were detected in the first cohort (Fig. 3). This
time, however, both of the two clones were co-dominant in
almost all animals simultaneously, even though with vary-
ing contributions. Analysis of the graft showed that both
clones were already more abundant, as 20.4% of all reads
represented barcode A, and 10.1% of all reads barcode B,
indicating a certain growth advantage in vitro.
Transcript level analysis
Several studies indicate that the amount of BcrAbl tran-
script is a major determinant to define the transition
from chronic phase CML to blast crisis (e.g. [40]). We
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established a qPCR method based on plasmid standards
(used in clinical diagnostics) to assess the BcrAbl abun-
dance in individual clones. In particular, we applied the
ΔΔCt-method [41] to calculate the amount of BcrAbl
transcripts in different BcrAbl clones in comparison to
the sorted BcrAbl_bulk culture. We found that clone A
contained 4.5× BcrAbl transcripts and clone B
2.9× more BcrAbl transcripts in comparison to the
BcrAbl_bulk culture (Fig. 4a).
Integration site analysis and transcriptomics
For further characterization of clones A and B, we per-
formed ligation-mediated (LM-)PCR of DNA extracted
from spleen of two diseased mice (clone A: mouse
#11104 and clone B: mouse #11125). In accordance with
the observed monoclonality we obtained one integration
site (IS) for each sample. The IS of clone A was identi-
fied on chromosome 3 in the proximity of the tumor-
suppressor gene Sprouty1 (Gene ID: 24,063). Clone B
harbored an IS on chromosome 13, localized down-
stream of the tumor suppressor Klf-6 (Gene ID: 23,849).
Both genes play a role in signaling pathways affected by
BcrAbl. We therefore reasoned that a cooperative effect
of the BcrAbl expression by dysregulation of genes close
to the integration site might have contributed to the
pronounced phenotype in vivo.
To further analyze the molecular basis of this clonal
competition phenomena, we performed RNA-sequencing
on 3 samples from both clones A and B and also 3 tech-
nical replicates of the controls. From the obtained reads
(mean: 33 × 106 reads per sample), we uniquely mapped
on average 71.4% of all reads per sample (69.8–73.2%) to
the mouse genome and analyzed the read counts for the
tumor suppressor genes Sprouty1 and Klf-6. Gene expres-
sion of Sprouty1 (Spry1) was almost undetectable in all
analyzed samples. On the contrary, Klf-6 (Klf6) was re-
liably expressed in the non-transduced Ba/F3 cells with
a 2- to 3-fold increase in clones A and B (Additional
file 1: Figure S5). Together, this data indicates that vec-
tor insertions had no major impact on the expression
of the two genes.
We analyzed the similarity in the gene expression
profiles, and observed a distinct clustering of the repli-
cates from clones A and B (based on Euclidian distance
Fig. 2 Final Analysis of the 1st mouse experiment. a eGFP expression in different hematopoietic organs (peripheral blood (PB), bone marrow (BM) and
spleen (Spl)) at final analysis on day 21 or 23 post transplantation in the six mice which developed leukemia. b Distribution of BcrAbl-containing clones
in the graft (d29), in the intermediate blood sample of day 11 post transplantation (d11) and in the hematopoietic organs. Genomic DNA was extracted
from samples and used for PCR-amplification of the barcode-containing sequences. Sequencing was performed on a Miseq-Instrument and obtained
sequences were analyzed by a customized R-script
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calculation) and a separation from the BcrAbl_bulk,
which is depicted in the corresponding heatmap and
further supported by principle component analysis
(Additional file 1: Figure S6A and B). We identified
5755 genes that were differentially expressed in the
clone A replicates (Fig. 4b), and 6556 differentially
expressed genes in the clone B replicates (Fig. 4c)
(FDR < 1). These genes were subjected to KEGG path-
way analysis [42], to investigate possible mechanisms
that might lead to the clonal success. We identified sev-
eral pathways, some of which are affected in infection
processes but also pathways relevant in signaling pro-
cesses associated with cancer (Additional file 1: Figure
S7). In contrast, we did not find any significant differ-
ences between clones A and B (Fig. 4d), thereby con-
firming the expressional similarity described above.
Simulation studies
In order to investigate the mechanisms of clonal success,
we performed simulation experiments with a single-cell
based mathematical model of hematopoietic tissue
maintenance [35, 36, 43] to test different assumptions
about the intrinsic heterogeneity of the transplanted
clones (Fig. 5).
We assumed that cells show differences in their clonal
proliferation ability or their competence to occupy
hematopoietic niches and additionally, that the cells dif-
fer in their ability for engraftment. From our model we
conclude, that a low overall engraftment is necessary to
reflect the cell number dependence of leukemia forma-
tion. Under the proposition that clones A and B are
structurally similar (as indicated by the parallel out-
growth in the second round of transplantations), the
situation of either clone A or clone B dominating can
only be reproduced if one but not the other clone en-
grafts. By the assumption that the engraftment efficacy
is slightly better for clone A and clone B in comparison
to all other transplanted cell clones, we were able to
achieve a scenario that we observed empirically. Due to
the sampling effect with the low numbers of
Fig. 3 Final Analysis of the 2nd mouse experiment. Distribution of BcrAbl-containing clones in the hematopoietic organs: peripheral blood (PB), bone
marrow (BM) and spleen (Spl). Genomic DNA was extracted from samples and used for PCR-amplification of the barcode-containing sequences.
Sequencing was performed on a Miseq-Instrument and obtained sequences were analyzed by a customized R-script. Clone A is marked in green,
clone B in blue, respectively
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transplanted cells, in most of the cases neither one of
the two clones engrafted (Fig. 6a). If there was an en-
graftment, most often only one clone promotes the
monoclonal leukemic outgrowth (Fig. 6b). Only an in-
crease in absolute cell numbers of clones A and B within
the prepared graft proved sufficient to explain not only
the increase in leukemic mice but also to ensure a paral-
lel engraftment of both leukemic clones (Fig. 6c).
Whether the dominance of clone A and B compared to
the BcrAbl_bulk results solely from a superior engraft-
ment or whether it is based on an additional proliferative
advantage conferred by the in vivo situation, cannot en-
tirely be disentangled based on the model structure.
Discussion
In this work we investigated the clonal competition dur-
ing leukemia outgrowth. To do so, we transduced mur-
ine Ba/F3 cells with barcoded γ- retroviral vectors,
encoding the BcrAbl-oncogene. Thus we generated a
BcrAbl_bulk population containing 158 different
barcoded clones. Time course of in vitro cultures re-
vealed fluctuations in clonal abundance, although the
overall clonal composition only changed moderately over
an observation period of 6 weeks. We observed a slow
decline in clone numbers as described for regular cell
culture [44]. However, we detected that the sorting of
transduced cells had a distinct impact on clone numbers
and clonal abundancies.
The clonal pattern changed once we transplanted
eGFP-positive barcoded cells into non-conditioned mice.
Six (of 15) animals transplanted with 10,000 transduced
cells in the first cohort developed leukemia within 21–
23 days. Barcode analysis revealed that the leukemias in
those animals were monoclonal (Fig. 2), thereby indicat-
ing that a distinct clonal advantage promoted engraft-
ment and outgrowth of defined cells only, whereas other
clones were unable to contribute to leukemia develop-
ment. Surprisingly, in the six leukemic mice only two
different dominant clones were identified (clone A: in 4/
6 animals, clone B: in 2/6 animals, Fig. 2). In a second
Fig. 4 BcrAbl transcript levels and differential gene expression. a BcrAbl transcript levels were measured by quantitative real-time PCR (qPCR). BcrAbl transcript
levels are increased in samples of clone A and B in comparison to samples of BcrAbl_bulk. b Differential expression among samples of clone A and
BcrAbl_bulk; c among samples of clones B and BcrAbl_bulk and d among samples of clones A and B (d). DESeq2-normalized mean expression (x axis;
log10 scale) and fold changes (y axis; log2 values) of differentially expressed (red) or unchanged (grey) genes (10% FDR) are indicated
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experiment, all transplanted mice developed leukemia,
which was not monoclonal as detected in the first co-
hort, but in most cases biclonal comprising both afore-
mentioned clones A and B (Fig. 3). Together this data
indicates that there was a threshold for the minimal
numbers of cells from leukemia-inducing clones A and
B that determined the experimental outcome. In fact, in
the 1000 cells cohort of experiment 1, an estimated
mean of only 5–6 cells from clones A and B were trans-
planted per animal, obviously insufficient to induce
leukemia. In the 10,000 cells cohort of experiment 1, cell
numbers were 10 times higher, and this number of ap-
proximately 100 (sum of A and B) cells was sufficient to
cause leukemia in 6/15 (40%) animals. In the second ex-
periment, the estimated number of cells representing
clones A and B was again more than 10 times larger,
which warranted leukemia outgrowth supported by both
clones in all animals.
To further analyze the mechanisms leading to the clonal
success in the two mouse experiments, we measured the
BcrAbl transcript levels in spleen cells taken from
leukemic mice and detected a higher abundance in both
clones A and B (Fig. 4a). The elevated BcrAbl levels in
clone A and B might have mediated their competitive ad-
vantage in the in vivo setting as suggested by earlier obser-
vations that BcrAbl expression increases with progression
of CML from chronic phase to blast crisis [40, 45].
RNA sequencing revealed that the tumor suppressor
genes in the genomic proximity of the proviral integra-
tions (namely Sprouty1 (clone A) and Klf-6 (clone B))
did not show significantly differential expression com-
pared to BcrAbl_bulk culture (Additional file 1: Figure
S5). This led us to conclude that the integration itself
did not substantially influence the functional behavior of
both clones by activating cooperative oncogenes or
downregulating tumor suppressors. However, looking at
the overall gene expression profile, we revealed a large
number of differentially deregulated genes (Fig. 4b-d) in
clones A and B compared with BcrAbl_bulk culture,
whereas we could not detect significant differences in
gene expression profiles between clones A and B. Ana-
lyzing pathways that contained deregulated genes, we
detected an abundance of pathways involved in disease
responses, especially during the process of viral or bac-
terial infection. Typically, NFκB – a protein involved in
multiple cellular responses – is present in all these path-
ways. NFκB is activated by the BcrAbl oncogene [46]
and responsible in the BcrAbl-mediated transformation
process [47, 48]. NFκB was also shown to be involved in
the regulation of hematopoietic stem cell renewal and
the interactions with the microenvironment of the
hematopoietic niche [49, 50]. We reasoned that NFκB-
driven responses might be a possible mechanism that
translates the elevated BcrAbl levels found in clones A
and B into a functional advantage of the corresponding
cells. A correlation of BcrAbl expression with engraft-
ment was also described by Krause et al. showing the de-
pendence of BcrAbl-positive cells on CD44 or selectins
for homing into the bone marrow [51, 52].
The higher BcrAbl expression in the two clones could
possibly be explained by the location of the vector inser-
tion in the genome, as there is a strong influence of the
genomic surrounding on the expression strength of inte-
grated retroviral vectors. Indeed, we have previously
shown that expression strength may vary by a factor of
four for single insertions [53], which might be explained
by their position to cis- or trans-regulating elements in
the nucleus [54].
Contrasting the moderate clonal conversion in the in
vitro setting with the rapid monoclonal outgrowth of
Fig. 5 Model concept of clonal leukemia. Within the mathematical model normal (white) hematopoietic stem cells compete with leukemic (grey,
blue, green) stem cells for niche space (lower, area A, no proliferation) in a stochastic activation/inactivation cycle (repeated changes to the
proliferative stage (upper, area Ω). Among the leukemic cells, the green clone (“A”) and the blue clone (“B”) have a higher probability
to occupy niche space (indicated by the size of the right vertical arrows) as compared to the other transformed Ba/F3 cells (BcrAbl_bulk indicated by the
grey cells) or the host cells (white). The in silico cells are also able to differentiate indicated by the horizontal arrows (top right)
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leukemia in vivo we investigated, which differentially regu-
lated mechanisms are conceptually suited to recover the
experimentally observed results. Using an established,
single-cell based mathematical model [35, 36, 43] of
hematopoietic self-maintenance we could only mimic the
experimental observations, if we assumed a low overall
engraftment probability for all transduced cells and an
additional difference between clones A, B and the
a
b
c
Fig. 6 Comparison with simulation studies. Frequency of clones is compared between transplantation studies and the corresponding model
simulations. a, b Percentages of recipients with no, monoclonal or biclonal leukemia for mouse transplantations with a 1000 and b 10,000 BcrAbl
transduced cells at d29. Given the low initial frequency, no leukemic engraftment is shown for the cohort receiving 1000 cells while low numbers
of monoclonally derived leukemias are observed in vivo and confirmed in silico for the cohort receiving 10,000 cells. c Composition of biclonal
leukemias (consisting of contributions from clone A and B) for the second cohort of transplantation at d45. A corresponding composition is
observed for the simulation studies
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remaining clones with respect to either their proliferative
capacity or their differential ability for initial engraftment.
Addressing a potential proliferative difference, earlier re-
sults on the BcrAbl-mediated induction of autocrine IL-3
secretion showed no direct effect in BaF3 cells [27]. How-
ever, it was shown for other cells lines that such an effect
can contribute to IL-3 independence [55, 56]. Although
we do not observe an advantage for clones A and B under
IL-3 deprivation in vitro conditions, we cannot rule out
that this selective effect promotes a proliferative clonal ad-
vantage of these cells in recipient animals.
Conclusions
Our findings represent a primary example to document
that clonal competition is not an absolute process, but
highly dependent on the environmental context. This
notion is intuitively accepted and already established in
the evolution of species. However, our exemplary study
documents that similar mechanisms also act in cancer
evolution, in which a broad spectrum of environmental
cues can determine the clonal composition and the time
scales of clonal dominance as well as the progression to
leukemia. We demonstrate that the effect of a prolifera-
tive advantage might only lead to clonal conversion in
the long run, whereas selective pressure (as exerted in a
transplantation setting) can lead to rapid changes in the
clonal repertoire. Similar processes are repeatedly dis-
cussed for the role of specific anti-cancer drugs promot-
ing the outgrowth of resistant clones that were
previously controlled in the polyclonal situation. As
such, the acquisition of secondary mutations (e.g., driv-
ing increased BcrAbl transcription) or even changes in
environmental factors (such as drug administration)
might distinctly alter the competitive advantage of a cell
clone, thereby accounting for accelerated leukemic ex-
pansion as observed during the transition from chronic
phase to blast crisis. Our study thus represents an im-
portant step towards understanding the broadness of
competition processes that lead to the manifestation of
leukemia.
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